Corcept Therapeutics Incorporated provided revenue guidance for the fiscal 2022. For the year, the company expects revenue guidance in the range of $400 million - $430 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.97 USD | -8.06% | -13.03% | -10.81% |
Jun. 14 | Global markets live: Tesco, Adobe, Tyson Foods, GameStop, Teva... | |
Jun. 14 | Teva Pharmaceutical Sues Corcept Therapeutics Alleging Market Monopolization for Cushing's Syndrome Drug Korlym | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.81% | 3.02B | |
+50.70% | 791B | |
+41.96% | 630B | |
-7.15% | 350B | |
+18.77% | 328B | |
+8.79% | 298B | |
+18.02% | 246B | |
+1.27% | 225B | |
+11.95% | 218B | |
+3.68% | 160B |
- Stock Market
- Equities
- CORT Stock
- News Corcept Therapeutics Incorporated
- Corcept Therapeutics Incorporated Provides Revenue Guidance for the Fiscal 2022